This study focuses on treating yeast intra-abdominal infection, a type of infection that occurs inside the abdomen, and peritonitis, which is inflammation of the tissue lining the inner wall of the abdomen. The study compares two treatments: caspofungin, a medication given through an intravenous line, and a placebo. The purpose is to determine if caspofungin can reduce the rate of treatment failure in patients who are in intensive care units after surgery for abdominal infections.
The medication being tested, caspofungin (brand name Cancidas), is available in two different strengths: 50 mg and 70 mg. It comes as a powder that is mixed with sodium chloride solution to create a liquid that can be given through a vein. The treatment period lasts for up to 8 weeks, during which patients receive daily doses of either caspofungin or placebo.
During the study, doctors will monitor patients for 28 days after starting treatment to see how well the medication works. They will also track patients’ progress for up to 90 days to gather additional information about the treatment’s effectiveness and safety. The study uses a double-blind design, which means neither the patients nor their doctors know who is receiving caspofungin or placebo during the treatment period.
France 
